Keyword: Biocryst

BioCryst says its BCX7353 drug effectively treated acute hereditary angioedema attacks in a midstage trial, setting up a possible registration study.

BioCryst’s shareholders voted down a proposal to merge with Idera Pharmaceuticals and form a combined rare disease company.